AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 to January 8, 2026, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws.
What if I purchased Aquestive Therapeutics securities?
If you purchased Aquestive Therapeutics securities during the Class Period and suffered losses, you have until May 4, 2026 to seek appointment as lead plaintiff. Investors who suffered significant losses and would like to discuss their rights, or to determine whether they qualify to participate in any potential recovery, should visit:
https://www.johnsonfistel.com/investigations/aquestive-therapeutics/
You may also contact James Baker at (619) 814-4471 or jimb@johnsonfistel.com, or Frank J. Johnson, Esq. at fjohnson@johnsonfistel.com to discuss your rights privately.
What is this case about?
According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Aquestive's New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling. On January 9, 2026, Aquestive announced that the Company was in receipt of a letter from the FDA identifying deficiencies that precluded labeling discussions for Anaphylm. Moreover, Aquestive revealed that the letter from the FDA confirmed that the Agency's review of Anaphylm NDA was ongoing and no final decision had been made, which effectively delayed the approval of Anaphylm well beyond the January 31, 2026 Prescription Drug User Fee Act date.
About Johnson Fistel, PLLP:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in securities class actions and shareholder derivative litigation, including international investors trading on U.S. exchanges. In 2024, the firm was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, recovering approximately $90.7 million for investors in cases where it served as lead or co-lead counsel.
Attorney Advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker or Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com | fjohnson@johnsonfistel.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
